» Articles » PMID: 38189822

From Complexity to Clarity: Unravelling Tumor Heterogeneity Through the Lens of Tumor Microenvironment for Innovative Cancer Therapy

Overview
Publisher Springer
Date 2024 Jan 8
PMID 38189822
Authors
Affiliations
Soon will be listed here.
Abstract

Despite the tremendous clinical successes recorded in the landscape of cancer therapy, tumor heterogeneity remains a formidable challenge to successful cancer treatment. In recent years, the emergence of high-throughput technologies has advanced our understanding of the variables influencing tumor heterogeneity beyond intrinsic tumor characteristics. Emerging knowledge shows that drivers of tumor heterogeneity are not only intrinsic to cancer cells but can also emanate from their microenvironment, which significantly favors tumor progression and impairs therapeutic response. Although much has been explored to understand the fundamentals of the influence of innate tumor factors on cancer diversity, the roles of the tumor microenvironment (TME) are often undervalued. It is therefore imperative that a clear understanding of the interactions between the TME and other tumor intrinsic factors underlying the plastic molecular behaviors of cancers be identified to develop patient-specific treatment strategies. This review highlights the roles of the TME as an emerging factor in tumor heterogeneity. More particularly, we discuss the role of the TME in the context of tumor heterogeneity and explore the cutting-edge diagnostic and therapeutic approaches that could be used to resolve this recurring clinical conundrum. We conclude by speculating on exciting research questions that can advance our understanding of tumor heterogeneity with the goal of developing customized therapeutic solutions.

Citing Articles

Precision medicine in gynecological cancer (Review).

Aravantinou-Fatorou A, Georgakopoulou V, Dimopoulos M, Liontos M Biomed Rep. 2025; 22(3):43.

PMID: 39810899 PMC: 11729136. DOI: 10.3892/br.2025.1921.


Substrate stiffness modulates extracellular vesicles' release in a triple-negative breast cancer model.

Senigagliesi B, Geiss O, Valente S, Vondracek H, Cefarin N, Ceccone G Extracell Vesicles Circ Nucl Acids. 2024; 5(3):553-568.

PMID: 39697626 PMC: 11648499. DOI: 10.20517/evcna.2024.47.


A comprehensive neuroimaging review of the primary and metastatic brain tumors treated with immunotherapy: current status, and the application of advanced imaging approaches and artificial intelligence.

Liu X, Chen H, Tan G, Zhong L, Jiang H, Smith S Front Immunol. 2024; 15():1496627.

PMID: 39669560 PMC: 11634813. DOI: 10.3389/fimmu.2024.1496627.


Tumor microenvironment and cancer metastasis: molecular mechanisms and therapeutic implications.

Biray Avci C, Bagca B, Nikanfar M, Takanlou L, Takanlou M, Nourazarian A Front Pharmacol. 2024; 15:1442888.

PMID: 39600368 PMC: 11588459. DOI: 10.3389/fphar.2024.1442888.


Emerging Role of Extracellular pH in Tumor Microenvironment as a Therapeutic Target for Cancer Immunotherapy.

Rahman M, Yadab M, Ali M Cells. 2024; 13(22).

PMID: 39594672 PMC: 11592846. DOI: 10.3390/cells13221924.


References
1.
Adedokun K, Oluogun W, Oyenike M, Imodoye S, Yunus L, Lasisi S . Expression Patterns of ER, PR, HER-2/neu and p53 in Association with Nottingham Tumour Grade in Breast Cancer Patients. Sultan Qaboos Univ Med J. 2023; 23(4):526-533. PMC: 10712386. DOI: 10.18295/squmj.7.2023.044. View

2.
Aderetti D, Hira V, Molenaar R, van Noorden C . The hypoxic peri-arteriolar glioma stem cell niche, an integrated concept of five types of niches in human glioblastoma. Biochim Biophys Acta Rev Cancer. 2018; 1869(2):346-354. DOI: 10.1016/j.bbcan.2018.04.008. View

3.
Albini A, Bruno A, Gallo C, Pajardi G, Noonan D, Dallaglio K . Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity. Connect Tissue Res. 2015; 56(5):414-25. PMC: 4673538. DOI: 10.3109/03008207.2015.1066780. View

4.
Asp M, Salmen F, Stahl P, Vickovic S, Felldin U, Lofling M . Spatial detection of fetal marker genes expressed at low level in adult human heart tissue. Sci Rep. 2017; 7(1):12941. PMC: 5636908. DOI: 10.1038/s41598-017-13462-5. View

5.
Assidicky R, Tokat U, Tarman I, Saatci O, Ersan P, Raza U . Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer. Breast Cancer Res Treat. 2022; 193(2):331-348. PMC: 9389626. DOI: 10.1007/s10549-022-06569-5. View